Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Neurimmune is a biopharmaceutical company dedicated to the development of innovative immunotherapeutics for human diseases. Its Reverse Translational Medicine™ platform generates recombinant human monoclonal antibodies with unique therapeutic properties. Together with target selectivity and high affinities these antibodies combine superior risk profiles with excellent efficacy.
Neurimmune has partnered four antibody programs with Biogen. Antibody Aducanumab (BIIB037) for Alzheimer's disease is currently in Phase 3 clinical trials. The therapeutic antibody for Parkinson’s disease (BIIB054) is in Phase 2. Therapeutic antibodies for tauopathies and fronto-temporal dementia are in preclinical stages.
Neurimmune’s program packages for amyotrophic lateral sclerosis, transthyretin amyloidosis and type-2 diabetes are validated with preclinical proof-of-concept. They are ready for partnering
